ABSTRACT A growing body of research has uncovered the role of long noncoding RNAs (lncRNAs) in multiple biological processes and tumorigenesis. Predicting novel interactions between diseases and lncRNAs could help decipher disease pathology and discover new drugs. However, because of a lack of data, inferring disease-lncRNA associations accurately and efficiently remains a challenge. In this paper, we present a novel network consistency projection for LncRNA-disease association prediction (NCPLDA) model by integrating the lncRNA-disease association probability matrix with the integrated disease similarity and lncRNA similarity. The lncRNA-disease association probability matrix is calculated based on known lncRNA-disease associations and disease semantic similarity. The integrated disease similarity and lncRNA similarity are computed based on disease semantic similarity, lncRNA functional similarity and Gaussian interaction profile kernel similarity. In leave-one-out cross validation experiments, NCPLDA achieved outstanding AUCs of 0.8900, 0.8996, and 0.9012 for three datasets. Furthermore, prostate cancer and ovarian cancer case studies demonstrated that the NCPLDA can effectively infer undiscovered lncRNAs.
I. INTRODUCTION
Long noncoding RNAs (lncRNAs) have a length greater than 200 nucleotides and were initially thought to be transcriptional noise; they are a class of important regulators of various cellular processes [1] - [3] , such as cell cycle control, translational and post-translational regulation, and chromatin modification. Not surprisingly, aberrant lncRNA expression can cause the initiation and progression of numerous human diseases [4] - [6] . Therefore, inferring disease-related lncRNAs can contribute to understanding the complex mechanisms underlying carcinogenesis at the lncRNA level and uncover new prognostic markers for disease diagnosis and therapy. However, experimentally verified lncRNA-disease relationships are still comparatively limited. Moreover, most
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biological experiments are laborious and costly. Accordingly, it is important to compute the association scores between diseases and lncRNAs using computational methods.
Over the past few years, some prediction models have been proposed to quantify the lncRNA-disease association probability based on multiple data types and sources [7] , [8] .
Recently, proposed models can be predominantly classified into three types. The first type of model makes use of known disease-related lncRNAs to infer new associations. Related studies are built on the basic view that similar diseases are likely to be linked with functionally similar lncRNAs. Chen and Yan [9] presented a computational method called LRL-SLDA to make prediction for lncRNA-disease pairs based on a Laplacian regularized least squares framework, which achieved reliable prediction by utilizing known interactions and lncRNA expression profiles. Sun et al. [10] developed RWRlncD, a global network-based method that constructs a lncRNA-lncRNA functional similarity network and performs random walks restarting to detect potential links. Afterwards, Chen et al. [11] proposed an improved model called IRWRLDA based on random walk, which sets the initial probability vector of lncRNAs by combining disease semantic similarity, lncRNA expression similarity, and known disease-lncRNA associations. Ping et al. [12] devised a new model based on a constructed bipartite network that relies on available disease-lncRNA network topological information. Yang et al. [13] presented an iterative model that integrates disease-lncRNA interactions and coding gene-disease interactions into a coding-noncoding gene-disease bipartite network; the model ranks the potential candidates for all diseases by applying a propagation algorithm to the newly constructed bipartite network. Ding et al. [14] applied a resource allocation algorithm on a gene-disease-lncRNA tripartite graph, integrating disease-gene interactions with disease-lncRNA interactions. However, most models of this type fail to identify interactions for new diseases or lncRNAs. The second type of model mines underlying disease-lncRNA pairs based on known disease (or lncRNA)-associated miRNAs or genes. Based on a hypergeometric distribution, Chen [15] designed the model of HGLDA, which scored each disease-lncRNA pair by testing whether this disease notably shared common microRNAs with lncRNA. Liu et al. [16] constructed a lncRNA prioritization model by integrating gene-disease interactions, gene expression profiles, and lncRNA expression profiles to prioritize novel disease-associated lncRNAs. Alaimo et al. [17] used the resource propagation technique to compute the weight between each disease-ncRNA pair by integrating disease-target interactions with ncRNA-target interactions. Later, Mori et al. [18] extended Alaimo's ncPred to make predictions, which integrated biological sequence information with weights computed by ncPred. The third type of models predicts possible associations between diseases and lncRNAs by combining multiple data sources. For instance, Chen [19] released a computational model termed KATZLDA to excavate latent lncRNA-disease associations by integrating known lncRNA-disease interactions and different types of lncRNA and disease similarity into a heterogeneous network. Fu et al. [20] presented a matrix factorization-based data fusion model to prioritize potential disease-related lncRNAs, which was capable of selecting and weighing different data sources. Lu et al. [21] developed a computational model named SIMCLDA using inductive matrix completion aiming to complete the missing lncRNAdisease interaction based on known interactions, lncRNA similarity data, and disease similarity data. Subsequently, a probabilistic model named NBCLDA was proposed by Yu et al. [22] . In NBCLDA, multiple heterogeneous kinds of biological data were combined to generate a tripartite network and a quadruple network, in which a naïve Bayesian classifier was applied for the prediction of latent diseaselncRNA interactions. Recently, Xiao et al. [23] developed a new computational path weighted method to compute the association score of each lncRNA-disease pair based on paths connecting them in a heterogeneous network, which was composed of known lncRNA-disease interactions, lncRNA similarity data, and disease similarity data. In addition, Lan et al. [24] integrated multiple data sources and utilized a bagging SVM classifier to mine latent relationships between diseases and lncRNAs. However, effectively fusing multiple heterogenous data sources is still a big challenge. Moreover, many models fail to identify interactions for new diseases, and some models need negative samples, which usually are unknown. Additionally, because of a lack of known association data, excavating the latent disease-lncRNA interactions accurately and efficiently remains a challenge.
In this paper, we propose the use of network consistency projection for lncRNA-disease association prediction (NCPLDA). NCPLDA computes the association score for each lncRNA-disease pair by integrating the lncRNA-disease association probability matrix with the integrated disease similarity and lncRNA similarity. To estimate the prediction accuracy of NCPLDA, leave-one-out cross validation was carried out on three datasets downloaded from the LncRNADisease database [25] . Moreover, we conducted two types of case studies to examine the practical ability of NCPLDA, including association prediction for diseases based on known interactions and for new diseases without any known related lncRNAs. NCPLDA performed well in the above experiments, which suggests that NCPLDA is effective in inferring latent interactions between lncRNAs and diseases.
Unlike the previous models, we predict the lncRNAdisease relationships according to a simple and effective algorithm (i.e., network consistency projection), which does not require negative instances and can greatly reduce the prediction time. In addition, a preprocessing procedure is adopted to derive the intermediate interaction probability of non-associated lncRNA-disease pairs that may be missed in the current databases. Such a consideration is often better for improving the prediction precision and enhancing predictions in the new disease cases.
II. MATERIALS AND METHODS

A. HUMAN LncRNA-DISEASE ASSOCIATIONS
The data of known lncRNA-disease associations were gathered from the LncRNADisease database. Three versions (June-2012 Version, January-2014 Version, and June-2015 Version) of LncRNADisease were used in the experiments. A few lncRNA-disease interactions with irregular lncRNA names or disease names were filtered out, and all repeating records were merged. As a result, the June-2012 Version (marked as DS1) consisted of 276 interactions between 112 lncRNAs and 150 diseases, the January-2014 Version (marked as DS2) consisted of 319 interactions between 131 lncRNAs and 169 diseases, and the June-2015 Version (marked as DS3) consisted of 621 interactions between 285 lncRNAs and 226 diseases. For convenience, we used an adjacency matrix A ∈ R m ×n to encode the lncRNA-58850 VOLUME 7, 2019 disease interactions with m lncRNAs as rows and n diseases as columns, where A(i, j) =1 if lncRNA i has association with disease j and 0 if not.
B. DISEASE SEMANTIC SIMILARITY
Recent research has increasingly demonstrated that disease semantic similarity aids in predicting disease-related ncRNAs [26] - [28] . Here, the calculation of the disease semantic similarity was identical to the method proposed by Wang et al. [29] , in which diseases are organized as directed acyclic graphs (DAGs). According to their corresponding DAGs, semantic similarities among all diseases were computed and the calculating process was illustrated by the DOSE software package [30] . Therefore, disease semantic similarity matrix SS can be obtained, where the element SS(d i , d j ) denotes the value of the semantic similarity between disease d i and disease d j .
C. LncRNA FUNCTIONAL SIMILARITY
It is observed that functionally similar lncRNAs are often linked with similar diseases [10] , [26] . Here, the calculation of the lncRNA functional similarity was identical to that in the previous study [10] , which computed functional similarity of two lncRNAs by estimating the semantic similarity of two disease sets that are associated with these two lncRNAs. Specifically, we supposed that lncRNA l i and lncRNA l j were related to m and n diseases, respectively. Thus, the similarity between lncRNA l i and lncRNA l j can be calculated by equations (1) and (2) as follows:
where FS is the lncRNA functional similarity matrix, D(l i ) indicates the disease set related to lncRNA l i . Note that disease similarity matrix SS and lncRNA similarity matrix FS are both sparse. Therefore, we further introduced the Gaussian interaction profile kernel similarity to alleviate this weakness.
D. GAUSSIAN INTERACTION PROFILE KERNEL SIMILARITY FOR LncRNAS AND DISEASES
Based on the notion that functionally similar lncRNAs tend to have similar association patterns with similar diseases and vice versa, a Gaussian interaction profile kernel similarity was constructed to measure lncRNA similarity and disease similarity. Firstly, we defined the association profile of lncRNA l i , which is a binary vector specifying the presence or absence of association with each disease. In fact, the association profile of lncRNA l i is the i-th row vector of the adjacency matrix A, i.e., A(i, :). Then, the similarity between lncRNA l i and l j can be computed by utilizing a Gaussian kernel function:
where γ l is charged with controlling the kernel bandwidth, which could be obtained by normalizing the original bandwidth γ . Here, γ is simply set to 1. Similarly, disease Gaussian interaction profile kernel similarity can be defined as follows:
where A(:, i) denotes the association profile of disease d i , and the parameter γ d is defined similarly as γ l .
E. INTEGRATED SIMILARITY FOR LncRNAS AND DISEASES
We combined lncRNA functional similarity FS with Gaussian interaction profile kernel similarity for lncRNA KL to construct the final lncRNA similarity matrix (LS). Specifically, for lncRNA l i and lncRNA
The combination is presented as follows:
Accordingly, we integrated semantic similarity SS and Gaussian interaction profile kernel similarity KD for diseases, and the final disease similarity matrix (DS) can be combined in the following manner:
As we know, existing lncRNA-disease interactions are very sparse [9] , [25] . In fact, many of the non-associated lncRNAdisease pairs in adjacency matrix A are unknown interactions [21] . Inspired by the solutions to new disease cases, we applied the WKNKN algorithm [31] as a preprocessing step to calculate the temporary interaction probability for these non-associated pairs according to their known neighbors. For instance, we estimate the interaction probability that lncRNA l i and disease d j interact. Firstly, we select K nearest known diseases as the neighbors of d j based on their semantic similarity to d j . Then, we compute the interaction probability profile for disease d j by using the weighted average of its neighbors' interaction profiles. We formulate the WKNKN as follows:
where
is the weight coefficient, where T is a decay term with T ≤ 1, and
is the normalization term. Finally, assuming A(l i , d j ) equals zero, we replace it with an intermediate interaction probability
G. NCPLDA METHOD
In this paper, we generated a novel computational model NCPLDA to infer lncRNA-disease relationships by using network consistency projection [32] . The implementation process of NCPLDA could be summarized in three steps (see Fig. 1 ). Firstly, we constructed the integrated disease similarity and lncRNA similarity by using disease semantic similarity, lncRNA functional similarity as well as known diseaselncRNA interactions. Secondly, we calculated the diseaselncRNA association probability matrix based on known disease-lncRNA interactions and disease semantic similarity. Lastly, we implemented the network consistency projection on lncRNA space and disease space respectively, and then we combined the results from these two spaces to obtain the final predictions.
NCPLDA measures the relevance between lncRNA l i and disease d j by combining two separate network consistency projection scores, i.e., the lncRNA space projection score and the disease space projection score. The projection of the lncRNA similarity network (denoted as matrix LS) on the lncRNA-disease association probability network (denoted as matrix A) represents the lncRNA space projection. Thus, the lncRNA space projection can be formulated in vector form as:
where LS (i, :) is a row vector representing the similarities between lncRNA l i and all other lncRNAs; A (:, j) is a column vector encoding the interactions between disease d j and all lncRNAs; |A(:, j)| denotes the length of vector A (:, j); and LSP (i, j) is the projection score of LS (i, :) on A (:, j). Obviously, the smaller angle between LS (i, :) and A(:, j), the more similar lncRNAs and lncRNA l i are, and the more lncRNAs related to disease d j , the higher the projection score LSP (i, j) is. Similarly, the projection of the disease similarity network (denoted as matrix DS) on the lncRNA-disease association probability network (denoted as matrix A) can be defined in a similar way:
where DSP (i, j) is the projection score of DS (:, j) on A(i,:). Finally, the lncRNA space projection score and the disease space projection score can be integrated and normalized as follows:
where NCP is the final network consistency projection score matrix, which quantifies the relevance between each lncRNA-disease pair. Algorithm 1 describes the implementation process of NCPLDA for disease-lncRNA association prediction. MAT-LAB code and datasets of NCPLDA can be accessed at https://github.com/ghli16/NCPLDA.
III. EXPERIMENTS AND RESULTS
A. EXPERIMENTAL SETTINGS
We conducted leave-one-out cross validation (LOOCV) to evaluate and compare the predictive accuracy of NCPLDA against other competitive methods, including SIMCLDA [21] , LRLSLDA [9] , and RWRlncD [10] . In LOOCV, for a given disease d i , each labeled d i -associated lncRNA is selected in turn as the testing sample, while other labeled lncRNA-disease interactions are deemed as the training set. All the unlabeled d i -associated lncRNAs, including the testing sample, comprise the candidate samples. After performing prediction, we ranked the association probability of the testing sample with the other candidate samples to judge whether the rank of the testing sample exceeded a given threshold. After each known association has been tested, the receiver operating characteristic (ROC) curve can be obtained, which plots the true positive rate (TPR) versus the false positive rate (FPR) at various cutoff points. From the ROC curve, the area under the curve (AUC) can be used to measure the overall performance of the model. Given that the Gaussian interaction profile kernel similarity and the association probability matrix are connected with known lncRNA-disease interactions, they need to be recalculated in each round of cross validation.
B. PARAMETER ANALYSIS
We investigated the impacts of the nearest neighbor number K and the decay term T on the performance of NCPLDA, where K and T range from 10 to 50 with step 10 and 0.1 to 0.9 with step 0.1, respectively. To search for proper values of K and T , we performed cross validation experiments using our three datasets. As shown in Fig. 2 , the AUC scores for the DS1 dataset were relatively robust for the change of K and T values. For instance, the maximal and minimal AUC values were 0.8900 and 0.8796 respectively. It means that there is no significant difference between them. In general, the AUC values just fluctuated within a 1.04% interval. Similar results were obtained for the DS2 and DS3 datasets for all K and T , which are illustrated in Supplementary Figs. S1 and S2. 
C. PERFORMANCE EVALUATION
To demonstrate the effectiveness of NCPLDA in predicting disease-lncRNA interactions, we implemented three representative methods (i.e., SIMCLDA, LRLSLDA, and RWRlncD) using the same three datasets. Fig. 3 shows the ROC curves for each method and reports their corresponding AUC scores for the DS1 dataset. The ROC curve of NCPLDA was clearly superior to those of the other methods in most cases, and NCPLDA had the best AUC (0.8900) among the approaches, whereas the AUCs of SIMCLDA, LRLSLDA, and RWRlncD were 0.8237, 0.6444, and 0.6886, respectively. Additionally, for the DS2 dataset, NCPLDA almost always achieved the highest TPR for the same FPR and obtained an AUC value of 0.8996, which was better than those of the other models (SIMCLDA: 0.8526; LRLSLDA: 0.6407; RWRlncD: 0.6803); the results are presented in Fig. 4 . We also provide the results for the DS3 dataset in Fig. 5 . Consistent with DS1 and DS2, NCPLDA yielded the highest AUC. The AUCs obtained for NCPLDA were 4.34%, 17.12%, and 28.91% higher than those obtained for SIMCLDA, LRLSLDA, and RWRlncD, respectively. In conclusion, these experimental results suggest that NCPLDA is an effective lncRNA-disease interaction prediction tool. 
D. CASE STUDIES
Two different types of case studies, on prostate cancer and ovarian cancer, were implemented to examine the practicability of NCPLDA in predicting novel disease-lncRNA interactions. For the first type of study, we used all known disease-lncRNA associated pairs from the DS3 dataset as training samples and selected the top 10 candidate lncRNAs as prediction lists for each investigated disease. The predicted associations were then checked by two other disease-lncRNA association databases: MNDR [33] and Lnc2cancer [34] .
We implemented NCPLDA for analysis of prostate cancer, and 9 out of the top 10 predicted lncRNA candidates were supported by either MNDR or Lnc2cancer (see Table 1 ). For instance, H19 has been found to be expressed in lower quantities in prostatic carcinoma cell lines (Du-145 and PC-3) than in normal cell lines [35] . Besides, the only unsupported lncRNA was BOK-AS1, which had been reported to be associated with prostate cancer in the literature [36] .
The top 10 ovarian cancer-associated candidates ranked by NCPLDA and the corresponding evidence are illustrated in Table 2 . The results showed 8 of the top 10 potential lncRNAs were found in public resources. As reported in [37] , lncRNA-HOTAIR plays a role in regulating cell invasion, migration, and proliferation of ovarian cancer through pro- moting the expression of PIK3R3. Moreover, we found that lncRNA-HOTAIR is also differentially expressed [38] .
For the second type of study, we constructed the NCPLDA model by eliminating all known association information of the watched disease from the DS3 dataset and then used the model to predict disease-lncRNA interactions. The top 10 predicted lncRNAs for prostate cancer and ovarian cancer and the evidence supporting these candidates are described in Table 3 and Table 4 , respectively. As the results show, all of the top 10 predictions for the two investigated diseases were verified as true by the DS3 dataset and/or the other two databases. Moreover, with all known disease-lncRNA associations of each disease considered as positive samples, NCPLDA was used to predict its interactions and achieved an average AUC score of 0.8951, suggesting that our method can predict latent disease-lncRNA interactions for new diseases with confidence. 
IV. CONCLUSION
Exploring disease-lncRNA relationships is not only the key to deciphering the mechanism of lncRNA-influencing diseases, but it is also important for curing diseases. In this study, we introduced a novel method, NCPLDA, for disease-lncRNA interaction prediction based on network consistency projection. In NCPLDA, the lncRNA space projection score and the disease space projection score were combined to compute the relevance score of each candidate lncRNA-disease pair. Compared with three previous methods, NCPLDA had higher accuracy in terms of AUC for three tested datasets. We also implemented two types of case studies, on prostate cancer and ovarian cancer, and found that more than 80% of lncRNA candidates in their top 10 predictions were validated by previous experimental reports. These results imply that NCPLDA is a promising tool for discovering more underlying disease-lncRNA associations.
The good prediction performance obtained by NCPLDA could be due to several reasons. First of all, we utilized the nearest-neighbor information to construct an intermediate association probability matrix, which could fill the incompleteness and sparsity of known associations. Secondly, NCPLDA could fully make use of the integrated similarity data of both the diseases and the lncRNAs, which can further enhance its detection results and make it applicable to isolated nodes. In the end, NCPLDA could mine hidden lncRNAs for all queried diseases on a large scale as a global ranking model.
Despite the commendable results obtained by NCPLDA, there are also several limitations that need to be further investigated. For example, NCPLDA depends on the quality of lncRNA-similarity and disease-similarity matrices. More biological information about lncRNAs and disease, such as gene-lncRNA and gene-disease interactions, could be integrated to further expand the model. Furthermore, we simply treated the disease space projection and the lncRNA space projection as being of equal importance, which might not be optimal. In addition, there are merely hundreds of known available disease-lncRNA interactions. The prediction accuracy of NCPLDA could be further enhanced when more experimentally verified relationships between diseases and lncRNAs are confirmed. 
